Home » Topics » BioWorld Science

BioWorld Science
RSS

Anthos Therapeutics studies MAA-868 in phase II for atrial fibrillation

Dec. 31, 2019

CTX-712: a novel promising CLK inhibitor for myeloid tumors

Dec. 31, 2019

BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder

Dec. 31, 2019

FDA approves OncoImmune's IND for anti-CTLA-4 antibody ONC-392

Dec. 31, 2019

Hookipa begins dosing in phase I/II trial of HB-201 for HPV16-positive cancers

Dec. 31, 2019

New phase Ib study evaluates mavorixafor with ibrutinib for Waldenstrom's macroglobulinemia

Dec. 31, 2019

Principia advances PRN-1008 for pemphigus with accelerated enrollment in phase III study

Dec. 31, 2019

Dybly describes new BRD4 inhibitors

Dec. 31, 2019

Qingdao Marine Biological Medicine Research presents EGF and FGF inhibitors

Dec. 31, 2019

BeiGene identifies new MAP4K1 inhibitors

Dec. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...